These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 23217597)

  • 1. National trends in anti-diabetic treatment in Taiwan, 2000-2009.
    Chang CH; Jiang YD; Chung CH; Ho LT; Chuang LM
    J Formos Med Assoc; 2012 Nov; 111(11):617-24. PubMed ID: 23217597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in antidiabetic medical treatment from 2005 to 2014 in Taiwan.
    Chu CH; Hsu CC; Lin SY; Chuang LM; Liu JS; Tu ST
    J Formos Med Assoc; 2019 Nov; 118 Suppl 2():S74-S82. PubMed ID: 31248659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in the prescription and cost of diabetic medications and monitoring equipment in England 1991-2004.
    Patel H; Srishanmuganathan J; Car J; Majeed A
    J Public Health (Oxf); 2007 Mar; 29(1):48-52. PubMed ID: 17124257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in the use of oral antidiabetic drugs by outpatients in Taiwan: 1997-2003.
    Chiang CW; Chiu HF; Chen CY; Wu HL; Yang CY
    J Clin Pharm Ther; 2006 Feb; 31(1):73-82. PubMed ID: 16476123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Costs of the treatment of hyperglycemia in patients with diabetes mellitus. The impact of age, type of therapy and complications: results of the German CoDiM study].
    von Ferber L; Köster I; Hauner H
    Med Klin (Munich); 2006 May; 101(5):384-93. PubMed ID: 16685485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in outpatient prescription drug costs in diabetic patients in Germany, 1994-2004.
    Rathmann W; Haastert B; Icks A; Giani G
    Diabetes Care; 2007 Apr; 30(4):848-53. PubMed ID: 17392545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A 50-year history of new drugs in Japan-the development and progress of anti-diabetic drugs and the epidemiological aspects of diabetes mellitus].
    Ozawa H; Murai Y; Ozawa T
    Yakushigaku Zasshi; 2003; 38(1):11-27. PubMed ID: 14570054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in Medicaid Reimbursements for Insulin From 1991 Through 2014.
    Luo J; Avorn J; Kesselheim AS
    JAMA Intern Med; 2015 Oct; 175(10):1681-6. PubMed ID: 26301721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between Gastroenterological Malignancy and Diabetes Mellitus and Anti-Diabetic Therapy: A Nationwide, Population-Based Cohort Study.
    Lin CM; Huang HL; Chu FY; Fan HC; Chen HA; Chu DM; Wu LW; Wang CC; Chen WL; Lin SH; Ho SY
    PLoS One; 2015; 10(5):e0125421. PubMed ID: 25978841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in oral antihyperglycemic and insulin use in the Nova Scotia senior population (1993-1999).
    Morningstar BA; Sketris IS; Kephart GC; Sclar DA
    Can J Clin Pharmacol; 2002; 9(3):123-9. PubMed ID: 12422249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct costs in diabetic and non diabetic people: the population-based Turin study, Italy.
    Bruno G; Picariello R; Petrelli A; Panero F; Costa G; Cavallo-Perin P; Demaria M; Gnavi R
    Nutr Metab Cardiovasc Dis; 2012 Aug; 22(8):684-90. PubMed ID: 21907553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Established therapies for diabetes mellitus.
    Hsia SH; Davidson MB
    Curr Med Res Opin; 2002; 18 Suppl 1():s13-21. PubMed ID: 12365815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in the use of antihypertensive drugs by outpatients with diabetes in Taiwan, 1997-2003.
    Chiang CW; Chen CY; Chiu HF; Wu HL; Yang CY
    Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):412-21. PubMed ID: 17252613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand.
    Chirakup S; Chaiyakunapruk N; Chaikledkeaw U; Pongcharoensuk P; Ongphiphadhanakul B; Roze S; Valentine WJ; Palmer AJ
    Value Health; 2008 Mar; 11 Suppl 1():S43-51. PubMed ID: 18387067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes.
    Cohen FJ; Neslusan CA; Conklin JE; Song X
    Diabetes Care; 2003 Jun; 26(6):1847-51. PubMed ID: 12766121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to oral antidiabetic agents with pioglitazone and metformin: comparison of fixed-dose combination therapy with monotherapy and loose-dose combination therapy.
    Barner JC
    Clin Ther; 2011 Sep; 33(9):1281-8. PubMed ID: 21840054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in the use of lipid-lowering drugs by outpatients with diabetes in Taiwan, 1997-2003.
    Chiang CW; Chiu HF; Chen CY; Wu HL; Yang CY
    Pharmacoepidemiol Drug Saf; 2008 Jan; 17(1):62-9. PubMed ID: 17924453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The increase in the use of drug treatment for diabetes mellitus in the Netherlands, 1998-2003].
    Langendam MW; Hooijkaas C; Piepenbrink JF
    Ned Tijdschr Geneeskd; 2006 Jun; 150(25):1396-401. PubMed ID: 16841589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors Contributing to the Rising National Cost of Glucose-Lowering Medicines for Diabetes During 2005-2007 and 2015-2017.
    Zhou X; Shrestha SS; Shao H; Zhang P
    Diabetes Care; 2020 Oct; 43(10):2396-2402. PubMed ID: 32737138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Oral hypoglycaemic agents in 2009].
    Schwab S; Diem P
    Ther Umsch; 2009 Oct; 66(10):677-84. PubMed ID: 19830675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.